JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB267042

Human IRF1 knockout A549 cell line

Be the first to review this product! Submit a review

|

(2 Publications)

IRF1 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp deletion in exon 2. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Cell Culture - Human IRF1 knockout A549 cell line (AB267042)
  • Cell Culture

Unknown

Cell Culture - Human IRF1 knockout A549 cell line (AB267042)

Representative images of IRF1 knockout A549 cells, low and high confluency examples (top left and right respectively) and wild-type A549 cells, low and high confluency (bottom left and right respectively) showing typical adherent, epithelial-like morphology. Images were captured at 10X magnification using an EVOS M5000 microscope.

Sanger Sequencing - Human IRF1 knockout A549 cell line (AB267042)
  • Sanger seq

Unknown

Sanger Sequencing - Human IRF1 knockout A549 cell line (AB267042)

Homozygous : 2 bp deletion in exon2

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp deletion in exon 2

Antibiotic resistance

Puromycin 1µg/mL

Disease

Carcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab267042-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255450 Human wild-type A549 cell line", "number":"AB267042-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab267042 Human IRF1 knockout A549 cell line", "number":"AB267042-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267042-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267042 Human IRF1 knockout A549 cell line", "number":"AB267042-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
IRF1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
  • Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium

F-12K + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

IRF1 also known as Interferon Regulatory Factor 1 is a transcription factor playing an important role in the regulation of interferon genes. This protein has a molecular weight of approximately 37 kDa. IRF1 is most commonly expressed in the nucleus but can be found elsewhere in the cell depending on the context. It operates by binding specific DNA sequences and influencing the transcription of genes involved in immune response.
Biological function summary

IRF1 influences cell growth arrest apoptosis and immune responses. It acts as an important regulator in the transcription of interferon-alpha and beta genes. IRF1 functions independently and is not generally part of a larger complex although it interacts with other transcription factors to modulate gene expression.

Pathways

IRF1 plays a significant role in both the type I interferon signaling pathway and the NF-kB pathway. These pathways are essential in the body's response to viral infections and inflammation. IRF1 interacts with proteins like STAT1 and NF-kB to initiate and regulate these immune responses effectively coordinating cellular reactions to external stress signals.

IRF1 has associations with cancer and autoimmune diseases. In several cancer types such as gastric cancer IRF1 expression levels can affect tumor suppression and progression. IRF1 also interacts with proteins like P53 in the context of cancer highlighting its role in immune and apoptotic pathways. In autoimmune conditions like multiple sclerosis altered IRF1 activity can impact disease severity and progression often through its interactions with other immune mediators.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

International journal of molecular sciences 25: PubMed38542436

2024

IRF1 Mediates Growth Arrest and the Induction of a Secretory Phenotype in Alveolar Epithelial Cells in Response to Inflammatory Cytokines IFNγ/TNFα.

Applications

Unspecified application

Species

Unspecified reactive species

Giulia Recchia Luciani,Amelia Barilli,Rossana Visigalli,Roberto Sala,Valeria Dall'Asta,Bianca Maria Rotoli

Biomedicines 11: PubMed37893073

2023

Cytokine-Induced iNOS in A549 Alveolar Epithelial Cells: A Potential Role in COVID-19 Lung Pathology.

Applications

Unspecified application

Species

Unspecified reactive species

Amelia Barilli,Giulia Recchia Luciani,Rossana Visigalli,Roberto Sala,Maurizio Soli,Valeria Dall'Asta,Bianca Maria Rotoli
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com